NCT04531943View on ClinicalTrials.gov

Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender Women

CompletedOBSERVATIONAL
Enrollment

285

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

April 4, 2024

Study Completion Date

April 4, 2024

Conditions
HIV Prevention
Interventions
DRUG

Estrogen

Feminizing hormone therapy consisting of estrogen alone, as prescribed by the participant's healthcare provider.

DRUG

Estrogen plus Progesterone

Feminizing hormone therapy consisting of estrogen and progesterone, as prescribed by the participant's healthcare provider.

Trial Locations (1)

30030

Hope Clinic, Atlanta

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Emory University

OTHER

NCT04531943 - Feminizing Hormone Therapy and the Rectal Mucosa Immune Environment in Transgender Women | Biotech Hunter | Biotech Hunter